Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT + Bezlotoxumab for CDI Recurrence in IBD Patients
NCT03829475Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2020
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bezlotoxumab in Clostridioides difficile infection (CDI), sponsored by Brigham and Women's Hospital. Started Jan 2020; status: completed.
02
Drugs
bezlotoxumab
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03829475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829475.